PVLA vs QNRX

Palvella Therapeutics, Inc. vs Quoin Pharmaceuticals, Ltd. — Valuation Comparison 2026

PVLA

Biotechnology
Palvella Therapeutics, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$115.86
Last close
Models
9/13
Active
VS

QNRX

Biotechnology
Quoin Pharmaceuticals, Ltd.
Quality
2.0
out of 10
Value Trap
Price
$4.94
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType PVLA Fair ValuePVLA Upside QNRX Fair ValueQNRX Upside
Bayesian DCF Intrinsic $38.72 -66.6% $1.31 -73.5%
Earnings Power Value Intrinsic $5.19 -95.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $17.71 -84.7% $4.38 -12.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PVLA vs QNRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PVLA vs QNRX — Which Stock Is More Undervalued?

PVLA scores higher with a 5.1/10 quality rating vs QNRX's 2.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Palvella Therapeutics, Inc. (PVLA) and Quoin Pharmaceuticals, Ltd. (QNRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PVLA currently trades at $115.86 with a QOC of 5.1/10, while QNRX trades at $4.94 with a QOC of 2.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).